CEO Greenleaf sells 360,540 shares (360.5K) at $7.96-$8.00 for $2.9M, reducing stake 16.8%
Greenleaf Peter, Chief Executive Officer of Aurinia Pharmaceuticals, executed 2 separate sales totaling 360,540 shares for $2,871,124.24 on 2025-03-03 and 2025-03-04, reducing his holdings from 2,149,485 to 1,788,945 shares. The sales occurred at prices ($8.00 and $7.92) near the current price of $8.08, while the stock trades 22.6% below its 52-week high of $10.44. Notably, his prior trade at AUPH (a sale on 2024-03-06) achieved a negative 90-day return of -5.9%, consistent with his cross-ticker track record showing a 100% well-timed rate on sells. The company's fundamentals remain solid: quarterly revenue of $67,771,000.00 with annual growth of 34.0% and positive net income of $14,350,000.00, suggesting the sales are not accompanied by obvious deteriorating business performance.